Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Then again the market may look upon it favourable as it could have been left in its original form which would of cost pharma companies a lot more. :-).
A key change is the provision allowing the federal Medicare health plan for older and disabled Americans to negotiate lower prescription drug prices. Copied .
Better to read the bill, it will explain it far better than me. :-)
Seaking1, surprised that pharma prices aren't already agreed before being used !!
Sold first buy of Thursday back yesterday Friday for 270p .
More then paid for bike repair .
Went to 275p by midday .
Biden is signing off a bill that will effect the pharma industry as firms will have to negotiate with the gov prices that they charge for drugs in the future.
Issue is alot clearer now after RNS update , should be a slow n steady rise back to 2.90p ish , probably couple of months.....GSK n Pfizer are the largest holders here bound to have a effect ....Gla
"May be required to indemnify GSK or Pfizer". Bizarre but surely most unlikely.
RR2022, another red share, like a bad smell or omen, everywhere you go is red! Here's another.
No wonder you never have an opinion anywhere, if you ever need lessons son just let me know.
Took their time. Could have made this announcement 24 hours ago.
Back up over 300 for W/E ?
Haleon PLC - Statement re Zantac
11 August 2022 22:20
WEYBRIDGE, UK / ACCESSWIRE / August 11, 2022 / Haleon plc (LSE:HLN) notes the
recent volatility in its share price and is aware of market speculation on
Haleon's potential liability in respect of Zantac product liability
litigation.
· Haleon is not aware of any material developments in relation to the Zantac
litigation since the Haleon prospectus was issued on 1 June 2022.
· Haleon is not a party to any of the Zantac claims.
· Haleon never marketed Zantac in any form in the U.S.
· Haleon is not primarily liable for any OTC or prescription claims.
· To the extent GSK and/or Pfizer are held liable in respect of OTC Zantac
during the periods outlined below, Haleon may be required to indemnify GSK
and/or Pfizer, only if the following conditions are met:
o GSK and/or Pfizer are unable to recover in respect of OTC Zantac from any
third parties who are ahead of Haleon and who have given indemnities under
previous transfers of rights to OTC Zantac; and
o Haleon is determined to be liable under the indemnification provisions among
Haleon, Pfizer and GSK.
Haleon told the media it is not a party of the litigation proceedings and it has never marketed the drug in any form in America.
Dumped is a bit harsh, whichever fund sold another fund bought . More buys than sells today .
Hi Rickengland,
As pockerchips says they don’t really pay it back it’s just a revolving door metaphorically speaking they just renegotiate the loans bonds over long time . The good news is they will chip away at the debit as they will have a large cashflow over the coming years from the greater number of products they sell I.e. toothpaste to painkillers . In regard to the div I personally haven’t a clue they may elect to pay one to keep shareholders happy or bang the first div into paying a bit of the debit off . I would like to see the debit being banged on the head a bit.
So not one other person is going to comment on the fact someone dumped 5 lots of £15 million yesterday and the effect that would of had on the share price? No one thinks £75 million is worthy of thought?
Recent large directors purchases eases concerns for me will top up next week if around these levels gla holders regards jack
Just seen by buy order at 245p lifted at 11.30am .
At 2pm its recovered to 265p above my to eager early buy .
your £18bn of liabilities merely tells part of the story... a reasonable amount are long term loans , and you need to weigh up that with what they are owed themselves etc ....get the full picture....look at the asset values the loans provide and the returns they produce (ROCE)
need to only really look at short term borrowings at present ...book shareholder equity is higher than the MCAP at present
" I'm trying to understand how they will pay it back "
they don't tend to pay it back....and the lenders dont want them to......they just renegotiate them and maybe pay off a part of them ....they merely aim to cover the yearly Finance costs
Dividends would come from cash flow and earnings performance
HLN are carrying £18bn of liabilities, a lot of that loans based on the prospectus. I'm trying to understand how they will pay it back on 343m profit and the impact t of that on potential divs.
So what have I missed that you feel there's value. Just trying to understand it that's all, against limited information.
Yes you are this ain’t cineworld. Read all the rns. Also upto date hon. Share news on the tab above. Then make your choice.
I'm interested in HLN, although currently trying to do some research.
In prospectus 343m profit / number of shares = 3.7p a share earnings. Thats not alot based on share pricem
Different number in prospectus lokoks like a typo in there earning per share quoted.
Threre's a ton of debt on the balance sheet , looks like cineworld territory. I am I missing something here?
Well I’ve added. Seems this has been exaggerated regarding the Zantac. We shall see good fall yesterday and more today it’s still the biggest consumer healthcare business around and at a low sp sharks would definitely be circling. :-)
At the end of yesterday someone dumped 75 million quids worth of shares, that had to scare off someone and/or flood the market dropping the price, that kind of movement must make people look and react to things they may of overlooked originally whilst they look for answers.
Haleon not a party to U.S. litigation focused on Zantac – spokesperson
11 August 2022 12:23
LONDON, Aug 11 (Reuters) – Haleon – GSK's recently spun off consumer health unit – is not a party to the U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday.
"We have never marketed Zantac in any form in the U.S., as Haleon or as GSK consumer healthcare," the spokesperson said in response to queries about sharp declines in Haleon shares.
Given over-the-counter Zantac has been sold by several companies over time, that "may make third parties liable ahead of any Haleon exposure," the spokesperson added.